Abstract
In the management of carcinoma of the esophagus, neoadjuvant chemoradiation has shown to improve survival in many Western studies. It has still not become the standard of care in many centers due to perioperative morbidity/mortality or non-availability of infrastructure. We carried out a retrospective comparative study of patients undergoing upfront surgery (group A) versus patients undergoing radical esophagectomy after neoadjuvant therapy (group B) during the period 2015 to 2019 by a single surgical team in our hospital. A total of 55 cases were recorded. Baseline demographic parameters were similar between the groups. Perioperative outcomes like duration of surgery, blood loss, anastomotic leak, hospital stay, and postoperative complications were similar in both groups. There were no significant differences in radicality of resection, nodal harvest, and margin status. Pathologic complete response was observed in 20% who received neoadjuvant therapy. After a median follow-up of 28 months, 72% were alive in the upfront surgery arm and 50% in the neoadjuvant therapy arm. The mean overall survival was 10.9 ± 8.9 months in group A and 12.8 ± 10.8 months in group B. There was no statistically significant difference in survival between the groups (p value 0.503). Radical esophagectomy after neoadjuvant therapy is a feasible and safe oncologic procedure. Careful case selection and surgical expertise are important determinants in perioperative outcome. Prospective randomized controlled trials with long-term follow-up will establish the standard of care in this subset of population.
Similar content being viewed by others
References
Ferlay J, Soerjomataram I, Ervik M et al. (2012). GLOBOCAN, cancer incidence and mortality worldwide: IARC cancer base no. 11 [internet]. Lyon, France: International Agency for Research on Cancer; 2013
National Cancer Registry 2004
Jha P, Gajalakshmi V, Gupta PC et al (2006) Prospective study of one million deaths in India: rationale, design, and validation results. PLoS Med 3:191–200
Kelsen DP, Winter KA, Gunderson LL et al (2009) Long-term results of RTOG trial 8911 (USA Intergroup113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 27:5062–5067
Allum WH, Stenning SP, Bancewicz J et al (2009) Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J ClinOncol 27:5062–5067
Van Hagen P, Hulshof MC, van Lanschot JJ (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084
Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J, Australasian Gastro-Intestinal Trials Group (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 8:226–234
Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V, Australasian Gastro-Intestinal Trials Group (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 12:681–692
Walsh TN, Noonan N, Hollywood D et al (1996) A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335(7):462–467
Bosset JF, Gignoux M, Triboulet JP et al (1997) Chemoradiotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. N Engl J Med 337(3):161–167
Shapiro J (2015 Sep) Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 16(9):1090–1098
Krishnamurthy A., Indian Journal Of Cancer Year : 2017 | Volume : 54 Issue : 4 | Neoadjuvant chemoradiation for locally advanced resectable carcinoma of the esophagus: a single-center experience from India with a brief review of literature
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Viswanathan, M.P., Suresh Kumar, D., Arul Kumar, G. et al. Analysis of Carcinoma of the Esophagus Patients Between Upfront Surgery vs. Neoadjuvant Therapy Followed by Surgery. Indian J Surg 82, 1026–1030 (2020). https://doi.org/10.1007/s12262-020-02156-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12262-020-02156-4